‘Lupin has gained significant momentum towards development of biosimilar products with primary focus on regulated markets’ Read more
‘Our turnover has grown 65 per cent in comparison to 2015-16. We are looking to grow 40 per cent this year’ Read more
‘We wish to equip the pharma sector with technology that seamlessly functions with highest accuracy’ Read more
Our primary business focus is on complex, regulated drug delivery devices and connected health solutions Read more